Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) today
announced it has engaged Intertek Cantox ("Cantox") to devise the drug
development plan for the Company's lead compound, GH501a. The Company recently
identified GH501a as a potential treatment for non-small cell lung cancer and
pancreatic cancer. 


The drug development plan is expected to be complete by the end of 2011 and will
focus in detail on the steps that need to be completed by the Company in order
to submit an Investigational New Drug ("IND") application and pursue subsequent
human trials.


About Intertek Cantox

Cantox is a leading international scientific and regulatory consultancy firm.
The Pharmaceuticals & Healthcare team assists companies with strategic planning
during the product development lifecycle, the management of nonclinical safety
testing programs to support clinical trials, preparation, review, and
compilation of regulatory submissions, and the provision of expert toxicology
and regulatory advice.


About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company that is developing
early stage proprietary technology for sale to pharmaceutical and industrial
companies.


The Company's majority owned subsidiary, Colorado Cancer Therapeutics ("CCT"),
currently holds an option to enter into an exclusive license with the University
of Colorado to commercialize a new class of anti-cancer compounds that includes
GH501a.


Together, Arch and CCT have up to January 1, 2012 to exercise the option before
proceeding with the confirmation of a candidate compound for an IND filing.


Arch has an option to buyout the remaining 1/3 of CCT it does not already own,
effective November 20, 2011 and expiring May 20, 2013.


For more information on the Company, please consult the other public documents
filed on SEDAR at www.sedar.com. 


The Company's website address is: www.archbiopartners.com. 

Intertek Cantox's website address is: www.cantox.com

Forward-Looking Statements 

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.
Indy Diarytech Limited Com (TSXV:IND)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Indy Diarytech Limited Com Charts.
Indy Diarytech Limited Com (TSXV:IND)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Indy Diarytech Limited Com Charts.